These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25619125)

  • 21. Heparins and venous thromboembolism: current practice and future directions.
    Prandoni P
    Thromb Haemost; 2001 Jul; 86(1):488-98. PubMed ID: 11487039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    Erkens PM; Prins MH
    Cochrane Database Syst Rev; 2010 Sep; (9):CD001100. PubMed ID: 20824828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.
    Zidane M; Schram MT; Planken EW; Molendijk WH; Rosendaal FR; van der Meer FJ; Huisman MV
    Arch Intern Med; 2000 Aug 14-28; 160(15):2369-73. PubMed ID: 10927736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-adjusted strategies in the prevention of early arterial thrombosis following lower extremity arterial reconstruction: a comparison of unfractionated versus low molecular weight heparin.
    Winkler MS; Larena-Avellaneda A; Diener H; Kölbel T; Debus ES
    J Cardiovasc Surg (Torino); 2013 Feb; 54(1 Suppl 1):183-92. PubMed ID: 23443603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
    Falciani M; Dilaghi B; Conti AA; Caciolli S; Gensini GF
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):27-35. PubMed ID: 11253337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis].
    Nielsen JD; Landorph A
    Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
    Kakkar VV; Boeckl O; Boneu B; Bordenave L; Brehm OA; Brücke P; Coccheri S; Cohen AT; Galland F; Haas S; Jarrige J; Koppenhagen K; LeQuerrec A; Parraguette E; Prandoni P; Roder JD; Roos M; Rüschemeyer C; Siewert JR; Vinazzer H; Wenzel E
    World J Surg; 1997 Jan; 21(1):2-8; discussion 8-9. PubMed ID: 8943170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Koppenhagen K; Kirchhof B; Weber U; Bergemann R
    Haemostasis; 1997; 27(2):75-84. PubMed ID: 9212355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
    Leizorovicz A; Siguret V; Mottier D; ; Leizorovicz A; Siguret V; Mottier D; Clonier F; Janas M; Stinson J; Townshend G; Maddalena M
    Thromb Res; 2011 Jul; 128(1):27-34. PubMed ID: 21477846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism.
    Graif A; Kimbiris G; Grilli CJ; Agriantonis DJ; Putnam SG; Leung DA
    J Vasc Interv Radiol; 2020 Apr; 31(4):537-543. PubMed ID: 31959518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
    Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
    Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Schramm W; Kirchhof B; Bergemann R
    Haemostasis; 1997; 27(2):65-74. PubMed ID: 9212354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.